| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Glioblastoma | D005909 | 27 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Zhu J et al. | Mevalonate-Farnesal Biosynthesis in Ticks: Comparative Synganglion Transcriptomics and a New Perspective. | 2016 | PLoS ONE | pmid:26959814 |
| Torabi S and Mo H | Trans, trans-farnesol as a mevalonate-derived inducer of murine 3T3-F442A pre-adipocyte differentiation. | 2016 | Exp. Biol. Med. (Maywood) | pmid:26660152 |
| Inoue Y et al. | Farnesol-Induced Disruption of the Staphylococcus aureus Cytoplasmic Membrane. | 2016 | Biol. Pharm. Bull. | pmid:27150138 |
| Léger T et al. | The Metacaspase (Mca1p) Restricts O-glycosylation During Farnesol-induced Apoptosis in Candida albicans. | 2016 | Mol. Cell Proteomics | pmid:27125826 |
| Cheng HL et al. | Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. | 2016 | Oncotarget | pmid:26848867 |
| Jung SI et al. | Comparison of E,E-Farnesol Secretion and the Clinical Characteristics of Candida albicans Bloodstream Isolates from Different Multilocus Sequence Typing Clades. | 2016 | PLoS ONE | pmid:26848577 |
| Brilhante RS et al. | Histoplasma capsulatum in planktonic and biofilm forms: in vitro susceptibility to amphotericin B, itraconazole and farnesol. | 2015 | J. Med. Microbiol. | pmid:25657300 |
| Leonhardt I et al. | The fungal quorum-sensing molecule farnesol activates innate immune cells but suppresses cellular adaptive immunity. | 2015 | MBio | pmid:25784697 |
| Horev B et al. | pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence. | 2015 | ACS Nano | pmid:25661192 |
| De Loof A | The essence of female-male physiological dimorphism: differential Ca2+-homeostasis enabled by the interplay between farnesol-like endogenous sesquiterpenoids and sex-steroids? The Calcigender paradigm. | 2015 | Gen. Comp. Endocrinol. | pmid:25540913 |